NASDAQ:TLGT

Teligent (TLGT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.01
$0.05
52-Week Range
N/A
Volume
6,460 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TLGT stock logo

About Teligent Stock (NASDAQ:TLGT)

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

TLGT Stock News Headlines

IDT Corp. Cl B
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
See More Headlines
Receive TLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teligent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/16/2021
Today
4/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TLGT
Employees
2,357
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Timothy B. Sawyer
    President, Chief Executive Officer & Director
  • Antonio di Nicola
    Vice President-Operations & General Manager
  • Alyssa Lozynski
    Chief Financial Officer
  • Devendra Shah
    Vice President-Research & Development
  • Philip K. Yachmetz
    Secretary, Chief Legal Officer & Executive VP

TLGT Stock Analysis - Frequently Asked Questions

How were Teligent's earnings last quarter?

Teligent, Inc. (NASDAQ:TLGT) released its earnings results on Monday, August, 16th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.01. The business earned $10.43 million during the quarter.

When did Teligent's stock split?

Teligent's stock reverse split before market open on Thursday, May 28th 2020. The 1-10 reverse split was announced on Wednesday, May 27th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Tim Sawyer's approval rating as Teligent's CEO?

2 employees have rated Teligent Chief Executive Officer Tim Sawyer on Glassdoor.com. Tim Sawyer has an approval rating of 100% among the company's employees. This puts Tim Sawyer in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Teligent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX), ChemoCentryx (CCXI), Voyager Therapeutics (VYGR), AbbVie (ABBV), General Electric (GE), Biocept (BIOC), Lannett (LCI), Pfizer (PFE), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

This page (NASDAQ:TLGT) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners